公开(公告)号：US20180017565A1

公开(公告)日：2018-01-18

申请号：US15546223

申请日：2016-01-27

申请人： ADELAIDE RESEARCH & INNOVATION PTY LTD

发明人： Martin K. Oehler ,  Carmela Ricciardelli ,  Noor Lokman ,  Peter Hoffmann

IPC分类号： G01N33/574

CPC分类号： G01N33/57449 ,  G01N2333/4718 ,  G01N2800/50

摘要： The present invention relates to a biomarker for early stage ovarian cancer. Specifically, expression of the biomarker Annexin A2 is higher in the plasma of subjects with early stage ovarian cancer. Accordingly, methods of detecting early stage ovarian cancer in a subject, of identifying a subject having early stage ovarian cancer, and of determining if a subject is susceptible to developing ovarian cancer, are provided. Also provided are methods of screening candidate therapeutic agents for use in treating early stage ovarian cancer, and compositions and kits for detecting early stage ovarian cancer in a subject, for identifying a subject having early stage ovarian cancer, and for determining if a subject is susceptible to developing ovarian cancer.

公开(公告)号：US09487831B2

公开(公告)日：2016-11-08

申请号：US14485206

申请日：2014-09-12

申请人： The University of Hong Kong

发明人： Stephanie Kwai Yee Ma ,  Man Tong ,  Xin-Yuan Guan

IPC分类号： G01N33/574 ,  C12Q1/68 ,  C12N15/113 ,  G01N33/50 ,  C07K16/18

CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K16/303 ,  C07K2317/14 ,  C07K2317/73 ,  C07K2317/76 ,  C12N15/1137 ,  C12N2310/11 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Y301/04003 ,  G01N33/5011 ,  G01N33/57438 ,  G01N2333/47 ,  G01N2333/4718 ,  G01N2333/916

摘要： Annexin A3 (ANAX3) is utilized as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma (HCC) and the utilization of a monoclonal antibody against ANXA3 or antisense polynucleotide against ANXA3 mRNA for the suppression or treatment of HCC, alone or in combination with other HCC treatment. Monoclonal antibody against ANXA3 can be administered for the suppression of tumor growth, metastasis, and chemoresistance.

摘要翻译： 膜联蛋白A3（ANAX3）用作肝细胞癌（HCC）的诊断和预后的生物标志物，并且单独或与其他组合使用针对ANXA3或反义多核苷酸的单克隆抗体针对ANXA3 mRNA用于抑制或治疗HCC 肝癌治疗。 可以施用针对ANXA3的单克隆抗体来抑制肿瘤生长，转移和化学耐药性。

公开(公告)号：US08409812B2

公开(公告)日：2013-04-02

申请号：US12770472

申请日：2010-04-29

申请人： Michael Cahill ,  André Schrattenholz

发明人： Michael Cahill ,  André Schrattenholz

IPC分类号： G01N33/53 ,  G01N33/567 ,  G01N33/574 ,  C07K14/00

CPC分类号： G01N33/57434 ,  G01N33/57446 ,  G01N2333/4718

摘要： A method treats urogenital and/or intestinal tract cancer and includes administering a therapeutically effective amount of at least one annexion protein, annexin of A3, to a mammal.

摘要翻译： 一种治疗泌尿生殖和/或肠道癌症的方法，包括向哺乳动物施用治疗有效量的至少一种附着蛋白，A3的膜联蛋白。

公开(公告)号：US08377648B2

公开(公告)日：2013-02-19

申请号：US12595678

申请日：2008-04-09

申请人： Andre Schrattenholz

发明人： Andre Schrattenholz

IPC分类号： G01N33/574

CPC分类号： G01N33/574 ,  G01N2333/4718

摘要： The present invention relates to a method for the diagnosis of prostate carcinoma comprising the determination of annexin A3 (ANXA3) and/or autoantibodies against ANXA3 with a specific reagent. The method allows differentiation between benign, premalignant and malignant conditions. Further, the method has a prognostic relevance.

摘要翻译： 本发明涉及一种用于诊断前列腺癌的方法，包括用特异性试剂测定膜联蛋白A3（ANXA3）和/或针对ANXA3的自身抗体。 该方法允许在良性恶变和恶性病症之间进行分化。 此外，该方法具有预后的相关性。

公开(公告)号：US20100240546A1

公开(公告)日：2010-09-23

申请号：US12408547

申请日：2009-03-20

申请人： Samuel Chun Lap Lo ,  Yoki Kwok Chu Butt ,  Wallace Woon Fong Leung

发明人： Samuel Chun Lap Lo ,  Yoki Kwok Chu Butt ,  Wallace Woon Fong Leung

IPC分类号： C40B30/04 ,  C12Q1/28 ,  C12Q1/37 ,  C12Q1/48 ,  C12Q1/34 ,  G01N33/68 ,  C12Q1/02 ,  G01N33/566 ,  G01N33/573 ,  G01N33/53

CPC分类号： G01N33/57423 ,  G01N2333/4718 ,  G01N2333/908 ,  G01N2333/912 ,  G01N2333/95 ,  G01N2800/52

摘要： A method for identifying, diagnosing, and monitoring cancerous lung tissues in a subject may include measuring the expression of at least one biomarker in a biological sample in the subject, and comparing the expression against a normal value. When a differential expression of the at least one biomarker between the biological sample and the normal value is more than 1.5-fold, the lung tissue sample is cancerous. The at least one biomarker is selected from the group consisting of peroxiredoxin I, peroxiredoxin II, peroxiredoxin III, peroxiredoxin IV, peroxiredoxin VI, chaperonin, amyloid-P-component, annexin V, dihydropyrimidinase-like 2 protein, glutamate carboxypeptidase, 2,3-bisphosphoglycerate mutase, thymidine phosphorylase, prolyl-4 hydroxylase, selenium binding protein 1, β-mitochondrial ATP synthase H+ transporting F1 complex, laminin-binding protein, minichromosome maintenance deficient protein 5 variant, keratin 9, keratin 10, napsin A aspartic peptidase, M2-type pyruvate kinase, and apolipoprotein A-I.

摘要翻译： 用于识别，诊断和监测受试者中的癌性肺组织的方法可包括测量受试者中生物样品中至少一种生物标志物的表达，并将该表达与正常值进行比较。 当生物样品和正常值之间的至少一种生物标志物的差异表达大于1.5倍时，肺组织样品是癌性的。 所述至少一种生物标志物选自过氧化物毒素I，过氧化物氧还蛋白II，过氧化物毒素III，过氧化还原毒素IV，过氧化还原毒素VI，伴侣蛋白，淀粉样蛋白-β-组分，膜联蛋白V，二氢嘧啶酶样2蛋白，谷氨酸羧肽酶，2,3 双磷酸甘油酸变位酶，胸苷磷酸化酶，脯氨酰基-4羟化酶，硒结合蛋白1，核糖体ATP合成酶H +转运F1复合物，层粘连蛋白结合蛋白，微染色体维持缺陷蛋白5变体，角蛋白9，角蛋白10，napsin A天冬氨酸肽酶 ，M2型丙酮酸激酶和载脂蛋白AI。

公开(公告)号：US20100173291A1

公开(公告)日：2010-07-08

申请号：US12451183

申请日：2008-05-01

申请人： Esther Guetta ,  Gad Barkai ,  Liat Gutstein-Abo

发明人： Esther Guetta ,  Gad Barkai ,  Liat Gutstein-Abo

IPC分类号： C12Q1/68 ,  G01N33/53 ,  C12Q1/02 ,  C12N5/02

CPC分类号： G01N33/5005 ,  C12N5/0603 ,  G01N33/689 ,  G01N2333/4718 ,  G01N2333/4742

摘要： Provided is a method of identifying a trophoblast by detecting in cells of a biological sample, with the proviso that the biological sample does not comprise a placental tissue, expression of a trophoblast marker selected from the group consisting of an annexin IV, a cytokeratin-7, a cytokeratin-8 and a cytokeratin-19; and classifying cells exhibiting expression of the trophoblast marker as trophoblasts. Also provided are methods of detecting a pregnancy in a subject, isolating trophoblasts from biological samples and prenatally diagnosing a conceptus using the identified trophoblasts.

摘要翻译： 提供了一种通过在生物样品的细胞中检测来鉴定滋养层细胞的方法，条件是生物样品不包含胎盘组织，滋养层标志物的表达选自膜联蛋白IV，细胞角蛋白-7 ，细胞角蛋白-8和细胞角蛋白-19; 并将表达滋养层标记物的细胞分类为滋养层。 还提供了检测受试者怀孕的方法，从生物样品中分离滋养层细胞，并使用鉴定的滋养层细胞预先诊断概念。

公开(公告)号：US20100008900A1

公开(公告)日：2010-01-14

申请号：US12172665

申请日：2008-07-14

申请人： Daniel Tak Chan ,  Susan Sou Ying Yung

发明人： Daniel Tak Chan ,  Susan Sou Ying Yung

IPC分类号： A61K39/395 ,  A61K38/02 ,  A61K31/711 ,  C12Q1/02 ,  A61P37/00 ,  A61P29/00

CPC分类号： G01N33/564 ,  A61K31/711 ,  A61K38/02 ,  A61K39/395 ,  A61K45/06 ,  C07K14/47 ,  C12N15/113 ,  C12N2310/14 ,  G01N2333/4718 ,  A61K2300/00

摘要： Methods and compositions for treating, detecting, diagnosing or assisting in the diagnosis of an inflammatory or immunological disorder are provided. The authors have made the novel discovery that anti-dsDNA antibodies are reactive to cell surface annexin II and through this interaction, anti-dsDNA antibodies are bound and then internalized and translocated into the cytoplasm and/or nucleus where they mediate altered cellular functions. Compositions that inhibit or interfere with the interaction of annexin II with anti-dsDNA antibodies can be used to treat one or more symptoms or pathological processes of an inflammatory or immunological disorder, preferably an auto-immune disorder. Methods for monitoring the progression or severity of an inflammatory or immunological disorder are also provided. In certain embodiments, levels of annexin II and/or anti-dsDNA antibodies, including anti-dsDNA antibodies that can bind to annexin II, are assessed and compared to a reference level of annexin II and/or anti-dsDNA antibodies that corresponds to a specific stage or severity of the disorder.

摘要翻译： 提供了用于治疗，检测，诊断或辅助诊断炎性或免疫学障碍的方法和组合物。 作者已经提出了抗dsDNA抗体对细胞表面膜联蛋白II具有反应性的新发现，并且通过这种相互作用，抗dsDNA抗体被结合，然后被内化并转移到细胞质和/或细胞核中，在此它们介导改变的细胞功能。 抑制或干扰膜联蛋白II与抗dsDNA抗体相互作用的组合物可用于治疗炎性或免疫学障碍，优选自身免疫性疾病的一种或多种症状或病理过程。 还提供了用于监测炎症或免疫学疾病进展或严重程度的方法。 在某些实施方案中，评估膜联蛋白II和/或抗dsDNA抗体（包括可以结合膜联蛋白II的抗dsDNA抗体）的水平，并将其与对应于α细胞膜的膜联蛋白II和/或抗dsDNA抗体的参考水平进行比较 疾病的特异性阶段或严重程度。

公开(公告)号：US20080171037A1

公开(公告)日：2008-07-17

申请号：US11890702

申请日：2007-08-07

申请人： Avi J. Ashkenazi ,  Scot A. Marsters ,  Robert Pitti

发明人： Avi J. Ashkenazi ,  Scot A. Marsters ,  Robert Pitti

IPC分类号： A61K39/395 ,  C07K14/00 ,  C07K16/00

CPC分类号： C07K14/70575 ,  A61K38/00 ,  C07K2317/24 ,  C07K2319/02 ,  G01N2333/4718

摘要： A tumor necrosis factor and lymphotoxin homolog having apoptotic activity, identified as Apo-3 Ligand, is provided. Nucleic acid molecules encoding Apo-3 Ligand, chimeric molecules and antibodies to Apo-3 Ligand are also provided.

摘要翻译： 提供了具有凋亡活性的肿瘤坏死因子和淋巴毒素同系物，鉴定为Apo-3配体。 还提供了编码Apo-3配体的核酸分子，嵌合分子和Apo-3配体的抗体。

公开(公告)号：US07323300B2

公开(公告)日：2008-01-29

申请号：US10295188

申请日：2002-11-15

申请人： John P. Fruehauf ,  Eugene Mechetner

发明人： John P. Fruehauf ,  Eugene Mechetner

IPC分类号： C12Q1/68 ,  C12P19/34 ,  C07H14/00

CPC分类号： G01N33/5091 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/142 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2333/4718 ,  G01N2800/44 ,  G01N2800/52

摘要： The invention provides methods for prognosis, diagnosis, staging and disease progression in human cancer patients related to expression levels of a plurality of genes that are differentially expressed in chemotherapeutic drug resistant and drug sensitive tumor cells.

摘要翻译： 本发明提供了与化疗药物抗性和药物敏感性肿瘤细胞中差异表达的多种基因的表达水平相关的人类癌症患者的预后，诊断，分期和疾病进展的方法。

公开(公告)号：US06830896B2

公开(公告)日：2004-12-14

申请号：US10294558

申请日：2002-11-15

申请人： Noboru Kaneko ,  Ryuko Matsuda ,  Tadahiro Kajita

发明人： Noboru Kaneko ,  Ryuko Matsuda ,  Tadahiro Kajita

IPC分类号： G01N33543

CPC分类号： G01N33/6893 ,  G01N2333/4718 ,  Y10S436/811

摘要： The present invention provides a process and regent for analyzing annexin-V, wherein the measurement of a concentration of annexin-V can be easily carried out without need for addition of chemicals for inhibiting the bonding of various proteins with calcium ion and for adjusting a specimen solution to the specimen at a measuring stage, and a process and medicine for diagnosing an internal organ disorder based on the analyzing process and regent. A urine is brought into contact with an anti-annexin-V monoclonal antibody to perform an antigen-antibody reaction of annexin-V in the urine with the anti-annexin-V monoclonal antibody, thereby forming an annexin-V antigen/anti-annexin-V monoclonal antibody complex, and the amount of the formed annexin-V antigen/anti-annexin-V monoclonal antibody complex is quantitatively measured. Thus, it is possible to carry out the measurement of the concentration of annexin-V in the urine, and it is possible to carry out the diagnosis of an internal organ disorder such as a disseminated intravascular coagulation syndrome, the diagnose of acute nephritis and the like by a analyzed value of concentration of annexin-V measured in the urine.

摘要翻译： 本发明提供了用于分析膜联蛋白-V的方法和试剂，其中可以容易地进行膜联蛋白-V浓度的测量，而不需要添加用于抑制各种蛋白质与钙离子结合的化学物质和用于调节样品 在测量阶段对标本的溶液，以及基于分析过程和摄取的诊断内脏器官障碍的过程和药物。 使尿液与抗膜联蛋白-V单克隆抗体接触，进行尿中与膜联蛋白-V单克隆抗体的膜联蛋白-V的抗原 - 抗体反应，从而形成膜联蛋白-V抗原/抗 - 膜联蛋白 -V单克隆抗体复合物，并定量测定形成的膜联蛋白-V抗原/抗 - 膜联蛋白-V单克隆抗体复合物的量。 因此，可以进行尿中膜联蛋白-V浓度的测定，可以进行内部器官功能障碍的诊断，例如弥漫性血管内凝血综合征，急性肾炎诊断和 如通过在尿液中测量的膜联蛋白-V浓度的分析值。